Statement from Acting OMB Director Robert Fairweather

**Budgetary Impact Analysis for Executive Order Entitled**

**“Improving and Expanding Access to Care and Treatments for COVID-19”**

This executive order directs the Department of Health and Human Services and the National Institutes of Health to enhance the Nation’s ability to quickly develop the most promising COVID-19 interventions by developing a plan to support a range of studies and research; directs targeted surge assistance to critical care and long-term care facilities; and requires the establishment of targets for the production, allocation, and distribution of COVID-19 treatments. Implementing this executive order would have de minimis impact on costs and revenues to the Federal Government. The benefits of this executive order include improving the capacity of the Nation’s healthcare systems to address COVID-19, accelerating the development of novel therapies to treat COVID-19, and improving all Americans’ access to quality and affordable healthcare. Implementing this executive order would have de minimis impact on mandatory and discretionary obligations and outlays, as well as on revenues to the Federal Government, in the 5-year fiscal period beginning in fiscal year 2021. The agencies anticipated to be impacted by this executive order include the Department of Health and Human Services, Defense, Veterans Affairs, and other relevant executive departments and agencies.